Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Turoctocog alfa pegol - Novo Nordisk

Next Previous
Drug Profile

Turoctocog alfa pegol - Novo Nordisk

Alternative Names: ESPEROCT; Long acting recombinant factor VIII - Novo Nordisk; N8-GP; N8-GP rFVIII; NN 7170; NN-7088; NNC-0129-0000-1003; PEG turoctocog alfa; Pegylated turoctocog alfa; rFVIII glycopegylated - Novo Nordisk

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Antihaemorrhagics; Blood coagulation factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemophilia A
  • New Molecular Entity No

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 17 Aug 2023 Novo Nordisk completes the phase-III trial Pathfinder6 in Haemophilia A (In children, In infants, In neonates, Treatment-naive) in USA, Algeria, Argentina, Australia, Austria, Bulgaria, Canada, France, Germany, Greece, Italy, Japan, Malaysia, Portugal, Romania, Spain, Taiwan and Thailand (IV) (NCT02137850) (EudraCT2013-004025-88)
  • 05 Jun 2023 Registered for Haemophilia A (Treatment-experienced) in Australia (IV)
  • 28 Dec 2022 Novo Nordisk completes the phase III trial Pathfinder10 in Haemophilia A (In adolescents, In adults, Treatment-experienced) in China (IV) (NCT05082116)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top